US EditionThe Geroprotectors Trametinib and Rapamycin Combine Additively to Extend Mouse Healthspan and Lifespan
- A study published on May 28 in Nature Aging revealed that administering a combination of the cancer drugs trametinib and rapamycin increased the lifespan of mice by as much as 30%.
- This study followed prior findings that each drug individually lengthened mouse lives and worked by inhibiting key cell signaling pathways involved in cancer and aging.
- Mice treated with both drugs showed delayed cancer onset, reduced inflammation, and improved heart and muscle health compared to controls receiving either drug alone.
- Co-Senior author Linda Partridge explained that although the significant lifespan increase seen in mice is unlikely to occur in humans, the medications under study may promote longer periods of good health and reduce disease during aging.
- The results suggest trametinib and rapamycin are promising geroprotectors that could soon enter human trials to explore their potential against age-related diseases.
13 Articles
13 Articles
Anti-aging drugs extend lifespan in mice, spark hope for human longevity Excerpt (117 characters):
In a quietly remarkable advance from European researchers, a pair of existing cancer drugs rapamycin and trametinib have been shown to extend the lifespans of mice by up to 35 percent. The study, conducted by scientists at the Max Planck Institute for Biology of Ageing in Germany, offers promising evidence that longevity-enhancing interventions might not only lengthen life but also delay the onset of age-related diseases. While rapamycin has lon…
The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan
Suppression of the insulin–IGF–mTORC1–Ras network ameliorates aging in animals. Many drugs have targets in the network because of its roles in cancer and metabolic disease and are candidates for repurposing as geroprotectors. Rapamycin, an established geroprotective drug, blocks mTORC1 signaling, and trametinib inhibits the Ras–MEK–ERK pathway. In this study, we assessed survival and health of male and female mice treated with trametinib, rapamyc
Combination drug therapy increases longevity by 30% in mice
According to a study, a combination of two cancer drugs, rapamycin and trametinib, can increase longevity in mice by 30% The research, published in Nature Aging, showed that the combination therapy showed greater effects than the individual drugs, offering longevity and health benefits in old age. The results suggest that the drugs could be promising for combating age-related diseases and extending life. Repurposing cancer drugs to tackle chroni…
Researchers say a combination of two anticancer drugs extends the lifespan of mice — and could help humans age better.
Coverage Details
Bias Distribution
- 75% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
